Twenty-five…that is the grand total number of U.S. patents owned by IlluminOss Medical, Inc. as of December 9, 2014. The company has just announced that it has been issued two new patents related to its internal bone fixation system. The patents include “kits for repairing a weakened or fractured bone, as well as internal bone fixation devices and systems for internal fixation of a fractured bone, and methods for internal fixation of a fractured bone.”
According to the December 10, 2014 news release, “The proprietary IlluminOss System incorporates the use of a thin-walled PET balloon that is infused with a liquid monomer and inserted into the intramedullary canal of the bone conforming to the shape of the patient’s specific bone. The device forms as an implant once the surgeon activates the visible light delivered within the PET balloon. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant.”
“2014 has been a pivotal year for IlluminOss, as we have continued to see successful results from the use of our orthopedic implant system in international markets and now the enrollment process is underway for our first U.S. clinical trial, ” said company President Robert Rabiner.
The company indicates that with its minimally invasive procedure patients are often back to daily activities more quickly than if they had been burdened with a hard cast. IlluminOss says that thus far, patients have experienced shorter procedure times, smaller incisions, and faster postop mobility. In addition, inpatient times and lower complication rates have also been reported.
Rabiner told OTW, “Our focus is to continue to make strides towards making IlluminOss’ approach to fracture repair a game changer in how orthopedic surgery will be performed worldwide. Over the next 12 months we will be collecting and analyzing data from our first U.S. clinical trial—which we expect will replicate the successful findings that have been achieved in Europe where the IlluminOss System has been effectively used in 700+ patient procedures, as well as two additional trials for new and increased clinical indications in Europe.”
